Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Faces Class Action Lawsuit Over Inaccurate Blood Test

XTALKS VITALS NEWS

Lawsuit

The lawsuit alleges that the company used deceptive advertising to mislead customers into believing that their blood testing methods were accurate.

Share this!

May 27, 2016 | by Sarah Massey, M.Sc.

Earlier this week, a class action lawsuit was filed in a federal court against controversial laboratory services company, Theranos Tweet: Class action lawsuit filed in a federal court against #Theranos http://ctt.ec/i661d+. The lawsuit alleges that the company used deceptive advertising to mislead customers into believing that their blood testing methods were accurate.

The lawsuit comes just weeks after Theranos announced that two years’ worth of testing results would be voided, and tens of thousands of corrected and revised results would be delivered to patients. The Centers of Medicare and Medicaid Services (CMS), are also considering banning Theranos’ co-founder, Elizabeth Holmes, from the blood testing industry for a two year period.

The Arizona man who filed the lawsuit is seeking damages and an order that the company stop engaging in false advertising. The man purchased a Theranos finger-prick blood test in December of 2015. According to the legal proceedings, the man would not have purchased the test had known that the Edison device did not work as advertised by the company.

The lawsuit claims that both the voided test results and the report filed after the CMS inspected Theranos’ Newark lab, suggest the company presented misleading information to consumers in regard to the accuracy of its testing methods. “As a result, tens of thousands of patients may have been given incorrect blood-test results, been subject to unnecessary or potentially harmful treatments, and/or been denied the opportunity to seek treatment for a treatable condition.”



According to Brooke Buchanan, a spokeswoman for Theranos, the lawsuit is “without merit” and the company plans to “vigorously defend itself against these claims.” Theranos made claims that the blood testing technology would allow for speedier, less-costly, point-of-care analysis.

Theranos formed a partnership with US pharmacy giant Walgreens in 2013, to allow for distribution of its tests. According to an article published in The Wall Street Journal, Walgreens failed to thoroughly asses the technology, as they were eager to quickly sign a deal with Theranos.

According to the lawsuit, the Walgreens deal legitimized Theranos’ testing claims, allowing the company to market their product to thousands of customers. While Theranos claimed their devices were compliant with regulations, Walgreens failed to do their due diligence to confirm those claims, before making a deal.


Keywords: Blood Test, Advertising, Lawsuit


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
GSK Malaria Vaccine to be Pilot Tested in Three African Countries

April 25, 2017 - Ghana, Kenya and Malawi will become the first countries to test GlaxoSmithKline’s (GSK) malaria vaccine in 2018.

Featured In: Life Science News


AbbVie Posts Late-Stage Clinical Trial Results for Chronic Hepatitis C Drug

April 24, 2017 - Patients with a traditionally challenging to treat subtype of hepatitis C may soon have a new treatment option for the chronic infection.

Featured In: Clinical Trials News


Study: Few Cardiovascular Benefits of Aspirin Therapy for Patients with Peripheral Vascular Disease

April 24, 2017 - A new study conducted by researchers at the University of Florida has found that aspirin therapy may not provide sufficient cardiovascular benefits for patients with peripheral vascular disease.

Featured In: Clinical Trials News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

A Holistic Understanding of the Patient Journey Using Multiple Data Sources


Addressing the Challenges of Type II Diabetes Global Clinical Trials via Use of High Quality Laboratory Solutions


Clinical Trial Considerations in Cerebral Protection for TAVR Patients


Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology


Copyright © 2016-2017 Honeycomb Worldwide Inc.